High Cholesterol & Dyslipidemia

About This Condition

Dyslipidemia — abnormal lipid levels in the blood — is a primary driver of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death in the United States. Standard lipid panels (total cholesterol, LDL-C, HDL-C, triglycerides) are a blunt instrument that misses significant cardiovascular risk in many patients. LDL cholesterol calculated by the Friedewald equation is notoriously inaccurate at lower levels and in the setting of elevated triglycerides. Small, dense LDL particles (sdLDL) and elevated LDL particle number (LDL-P) are far stronger predictors of cardiovascular events than LDL-C alone. Metabolic drivers — particularly insulin resistance and excess dietary refined carbohydrates — are frequently the primary cause of the most common dyslipidemia pattern (low HDL, high triglycerides, normal-appearing LDL with elevated particle count).

Our Approach

We order advanced cardiovascular lipid panels including LDL particle number (NMR LipoProfile or equivalent), sdLDL, Lp(a), ApoB, and ApoA1. We assess insulin resistance as a primary driver of atherogenic dyslipidemia and treat it accordingly. For patients with genuine LDL elevation, we individualize statin selection based on pharmacogenomics where indicated, and offer alternatives (ezetimibe, bempedoic acid, red yeast rice in appropriate patients) for statin-intolerant patients. We also use coronary artery calcium (CAC) scoring — obtained via referral — to stratify true cardiovascular risk, allowing us to avoid overtreatment in low-risk patients and aggressively treat genuinely high-risk individuals. Dietary intervention is protocol-driven, not generic.